Search

Search Constraints

You searched for: Author/Creator Busch, Raymonde

Search Results

1. Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. (1st December 2016)

2. FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia. Issue 2 (1st February 2017)

3. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Issue 7 (July 2016)

4. Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group. Issue 3 (3rd March 2016)

5. Poor efficacy and tolerability of R‐CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Issue 12 (26th September 2014)

6. Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer. Issue 7 (4th May 2007)

7. Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. Issue 8 (August 2013)

8. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T‐cell prolymphocytic leukemia. Issue 12 (19th March 2013)

9. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T‐cell prolymphocytic leukemia. Issue 12 (19th March 2013)